Akinsanya Karen

SEC source: 0001797672-26-000006 · wk-form4_1790025313.xml · derivative · entry 4

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,599

Underlying: Common Stock · 31,599 shares

Expires 2028-11-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.

F3 · derivative.exercise_date: This option was granted on November 29, 2018 and is fully vested.

SEC source: 0001797672-26-000006 · wk-form4_1790025313.xml · nonDerivative · entry 3

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,956

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.

F2 · balance_after: Includes 63,545 unvested RSUs.

SEC source: 0001797672-26-000006 · wk-form4_1790025313.xml · nonDerivative · entry 2

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,555

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.

F2 · balance_after: Includes 63,545 unvested RSUs.

SEC source: 0001797672-26-000006 · wk-form4_1790025313.xml · nonDerivative · entry 1

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,555

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.

F2 · balance_after: Includes 63,545 unvested RSUs.

SEC source: 0001797672-26-000004 · wk-form4_1782159237.xml · derivative · entry 1

Akinsanya Karen · CIK 0001797672 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2036-06-18

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

SEC source: 0001797672-26-000002 · wk-form4_1772836032.xml · nonDerivative · entry 1

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,956

F1 · kind: This sale was effected pursuant to a durable automatic sale instruction under Rule 10b5-1 adopted by the reporting person on March 8, 2023, represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ("RSUs"). The sale does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.71 to $13.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) of this Form 4.

F3 · balance_after: Includes 63,545 unvested RSUs

SEC source: 0001797672-26-000001 · wk-form4_1772573497.xml · derivative · entry 5

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,500

Underlying: Common Stock · 48,500 shares

Expires 2036-03-02

F7 · derivative.exercise_date: The option was granted on March 2, 2026. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 2, 2027 and the remainder are scheduled to vest in equal monthly installments through March 2, 2030, subject to the reporting person's continued service with the company.

SEC source: 0001797672-26-000001 · wk-form4_1772573497.xml · nonDerivative · entry 4

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,322

F4 · kind: This sale was effected pursuant to a durable automatic sale instruction under Rule 10b5-1 adopted by the reporting person on March 8, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PRSUs. The sale does not represent a discretionary trade by the reporting person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.70 to $12.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) of this Form 4.

F6 · balance_after: Includes an aggregate of 67,451 unvested RSUs.

SEC source: 0001797672-26-000001 · wk-form4_1772573497.xml · nonDerivative · entry 3

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,528

F3 · kind: Represents PRSUs previously granted to the reporting person on March 4, 2024, for which the compensation committee of the Issuer's board of directors certified on March 2, 2026 the level of achievement of the performance metrics for the PRSUs. The PRSUs will vest upon the filing of the Issuer's Annual Report on Form 10-K for the year ended December 31, 2026, subject to the reporting person's continued service with the company.

SEC source: 0001797672-26-000001 · wk-form4_1772573497.xml · nonDerivative · entry 2

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,952

F2 · kind: Represents the portion of the performance-based restricted stock units ("PRSUs") that were previously granted to the reporting person on February 9, 2023 in connection with the Issuer's annual grant of equity in 2023, that vested on March 2, 2026 following certification by the compensation committee of the Issuer's board of directors of the level of achievement of certain performance metrics for the PRSUs.

SEC source: 0001797672-26-000001 · wk-form4_1772573497.xml · nonDerivative · entry 1

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,875

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on March 2, 2026 and will vest in equal installments on each of March 9, 2027, 2028, 2029 and 2030, subject to the reporting person's continued service with the company.

SEC source: 0001808805-25-000060 · wk-form4_1750883807.xml · derivative · entry 1

Akinsanya Karen · CIK 0001797672 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2035-06-23

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

SEC source: 0001490978-25-000036 · wk-form4_1744749073.xml · derivative · entry 7

Akinsanya Karen · CIK 0001797672 · President of R&D, Therapeutics

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,345 shares

Expires 2027-10-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2024.

F6 · derivative.exercise_date: The option was granted on October 10, 2017 and is fully vested.

SEC source: 0001490978-25-000036 · wk-form4_1744749073.xml · derivative · entry 6

Akinsanya Karen · CIK 0001797672 · President of R&D, Therapeutics

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,378 shares

Expires 2028-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2024.

F5 · derivative.exercise_date: The option was granted on August 3, 2018 and is fully vested.

SEC source: 0001490978-25-000036 · wk-form4_1744749073.xml · nonDerivative · entry 5

Akinsanya Karen · CIK 0001797672 · President of R&D, Therapeutics

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,625

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2024.

F2 · balance_after: Includes 15,625 unvested RSUs.

SEC source: 0001490978-25-000036 · wk-form4_1744749073.xml · nonDerivative · entry 4

Akinsanya Karen · CIK 0001797672 · President of R&D, Therapeutics

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,970

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (4) of this form 4.

F2 · balance_after: Includes 15,625 unvested RSUs.

SEC source: 0001490978-25-000036 · wk-form4_1744749073.xml · nonDerivative · entry 3

Akinsanya Karen · CIK 0001797672 · President of R&D, Therapeutics

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,970

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (4) of this form 4.

F2 · balance_after: Includes 15,625 unvested RSUs.

SEC source: 0001490978-25-000036 · wk-form4_1744749073.xml · nonDerivative · entry 2

Akinsanya Karen · CIK 0001797672 · President of R&D, Therapeutics

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2024.

F2 · balance_after: Includes 15,625 unvested RSUs.

SEC source: 0001490978-25-000036 · wk-form4_1744749073.xml · nonDerivative · entry 1

Akinsanya Karen · CIK 0001797672 · President of R&D, Therapeutics

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,003

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2024.

F2 · balance_after: Includes 15,625 unvested RSUs.

SEC source: 0001490978-25-000021 · wk-form4_1741127348.xml · derivative · entry 2

Akinsanya Karen · CIK 0001797672 · President of R&D, Therapeutics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Common Stock · 62,500 shares

Expires 2035-03-03

F3 · derivative.exercise_date: The option was granted on March 3, 2025. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 3, 2026 and the remainder are scheduled to vest in equal monthly installments through March 3, 2029.

SEC source: 0001490978-25-000021 · wk-form4_1741127348.xml · nonDerivative · entry 1

Akinsanya Karen · CIK 0001797672 · President of R&D, Therapeutics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,625

F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on March 3, 2025 and will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service with the company.

F2 · balance_after: Includes 15,625 unvested RSUs.

SEC source: 0001808805-24-000051 · wk-form4_1718660424.xml · derivative · entry 1

Akinsanya Karen · CIK 0001797672 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2034-06-14

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

SEC source: 0001628280-24-008959 · wk-form4_1709675058.xml · derivative · entry 1

Akinsanya Karen · CIK 0001797672 · President of R&D, Therapeutics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2034-03-04

F1 · derivative.exercise_date: The option was granted on March 4, 2024. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 4, 2025 and the remainder are scheduled to vest in equal monthly installments through March 4, 2028.

SEC source: 0001808805-23-000057 · wf-form4_168695948494043.xml · derivative · entry 1

Akinsanya Karen · CIK 0001797672 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2033-06-15

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

SEC source: 0001490978-23-000011 · wf-form4_167606638377104.xml · derivative · entry 1

Akinsanya Karen · CIK 0001797672 · President of R&D, Therapeutics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,270

Underlying: Common Stock · 63,270 shares

Expires 2033-02-09

F1 · derivative.exercise_date: The option was granted on February 9, 2023. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 9, 2024 and the remainder are scheduled to vest in equal monthly installments through February 9, 2027.

SEC source: 0001808805-22-000069 · wf-form4_165542418669211.xml · derivative · entry 1

Akinsanya Karen · CIK 0001797672 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,411

Underlying: Common Stock · 14,411 shares

Expires 2032-06-15

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

SEC source: 0001808805-22-000033 · wf-form4_164876493974351.xml · derivative · entry 1

Akinsanya Karen · CIK 0001797672 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,998

Underlying: Common Stock · 105,998 shares

Expires 2032-03-30

F1 · derivative.exercise_date: In connection with the appointment of the Reporting Person to the Issuer's board of directors (the "Board") on March 30, 2022, the Reporting Person automatically received the Option (the "Initial Award") under the Issuer's Outside Director Compensation Policy and in accordance with the Issuer's 2021 Equity Incentive Plan (the "Plan"). Subject to the Reporting Person's continuous status as a "Service Provider" (as defined in the Plan), the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the Initial Award's grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). The grant date is March 30, 2022.

SEC source: 0001209191-22-008272 · doc4.xml · derivative · entry 1

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2032-02-09

F1 · derivative.exercise_date: The option was granted on February 9, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 9, 2023 and the remainder are scheduled to vest in equal monthly installments through February 9, 2026.

SEC source: 0001209191-21-060945 · doc4.xml · derivative · entry 3

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,198

Underlying: Common Stock · 1,393 shares

Expires 2028-11-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

F2 · derivative.exercise_date: This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.

SEC source: 0001209191-21-060945 · doc4.xml · nonDerivative · entry 2

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

SEC source: 0001209191-21-060945 · doc4.xml · nonDerivative · entry 1

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,393

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

SEC source: 0001209191-21-056425 · doc4.xml · derivative · entry 3

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,591

Underlying: Common Stock · 1,394 shares

Expires 2028-11-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

F2 · derivative.exercise_date: This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.

SEC source: 0001209191-21-056425 · doc4.xml · nonDerivative · entry 2

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

SEC source: 0001209191-21-056425 · doc4.xml · nonDerivative · entry 1

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,394

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

SEC source: 0001209191-21-051910 · doc4.xml · derivative · entry 8

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,378

Underlying: Common Stock · 13,377 shares

Expires 2028-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

F6 · derivative.exercise_date: The option was granted on August 3, 2018. The shares underlying the option are scheduled to vest in equal yearly installments from May 14, 2018 through May 14, 2022.

SEC source: 0001209191-21-051910 · doc4.xml · derivative · entry 7

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,985

Underlying: Common Stock · 4,180 shares

Expires 2028-11-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

F5 · derivative.exercise_date: This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.

SEC source: 0001209191-21-051910 · doc4.xml · derivative · entry 6

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,478

Underlying: Common Stock · 20,181 shares

Expires 2030-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

F4 · derivative.exercise_date: This option was granted on February 5, 2020. The shares underlying the option vested with respect to 25% of the shares on February 5, 2021 and the remainder are scheduled to vest in equal monthly installments through February 5, 2024.

SEC source: 0001209191-21-051910 · doc4.xml · nonDerivative · entry 5

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.905 to $58.86, inclusive.

SEC source: 0001209191-21-051910 · doc4.xml · nonDerivative · entry 4

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,047

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.90 to $57.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (3) of this Form 4.

SEC source: 0001209191-21-051910 · doc4.xml · nonDerivative · entry 3

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,738

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

SEC source: 0001209191-21-051910 · doc4.xml · nonDerivative · entry 2

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,361

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

SEC source: 0001209191-21-051910 · doc4.xml · nonDerivative · entry 1

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,181

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.

SEC source: 0001209191-21-039215 · doc4.xml · derivative · entry 7

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,165

Underlying: Common Stock · 10,242 shares

Expires 2028-11-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2021.

F5 · derivative.exercise_date: This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.

SEC source: 0001209191-21-039215 · doc4.xml · nonDerivative · entry 5

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.00 to $76.16, inclusive.

SEC source: 0001209191-21-039215 · doc4.xml · nonDerivative · entry 4

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 800

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.95, inclusive.

SEC source: 0001209191-21-039215 · doc4.xml · nonDerivative · entry 3

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,242

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2021.

SEC source: 0001209191-21-039215 · doc4.xml · derivative · entry 6

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,407

Underlying: Common Stock · 6,479 shares

Expires 2028-11-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2021.

F5 · derivative.exercise_date: This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.

SEC source: 0001209191-21-039215 · doc4.xml · nonDerivative · entry 2

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4.

SEC source: 0001209191-21-039215 · doc4.xml · nonDerivative · entry 1

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,479

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2021.

SEC source: 0001209191-21-016077 · doc4.xml · derivative · entry 1

Akinsanya Karen · CIK 0001797672 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2031-02-27

F1 · derivative.exercise_date: The option was granted on February 27, 2021. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 27, 2022 and the remainder are scheduled to vest in equal monthly installments through February 27, 2025.